News

Rockville Economic Development, Inc. (REDI) is set to launch its first BioBoost series on March 20, 2024, in Rockville, MD. This pioneering event, titled “The Future of Bio/Life Science Funding in 2024,” promises to be a cornerstone for professionals in the bio/life science sector. Attendees will have the unique opportunity to delve into the latest investment trends, overcome industry challenges, and discover new funding opportunities through insightful discussions led by esteemed industry experts.

In honor of Women’s History Month, which kicks off today, we wanted to highlight 10 incredible women making a mark in the life sciences in the BioHealth Capital Region. This is just the tip of the iceberg.

Arti Santhanam, Executive Director, Emerging Technology Centers (ETC)
Dr. Arti Santhanam was recently appointed Executive Director of Emerging Technology Centers (ETC). While new to the role, Dr. Santhanam is a long-time player in the BioHealth Capital Region.

Dr. Santhanam’s contributions over the last decade at TEDCO, especially within her role in the Maryland Innovation Initiative (MII), have been instrumental in fostering Maryland’s diverse and innovative ecosystem. Established in 2012, MII has invested $52.3M, resulting in 176 startups from notable universities like Johns Hopkins, the University of Maryland, and Morgan.

Maryland company continues toward goal of supporting improved patient safety

COLUMBIA, Md. (February 29, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $400,000 investment into Linshom Medical, Inc., a medical device company developing an innovative wearable sensor technology to support patient respiratory monitoring. This recent investment came in two parts – $250,000 from the State Small Business Credit Initiative (SSBCI) funding and $150,000 from the Venture Funds – and was done in conjunction with Abell Foundation.

TEDCO’s SSBCI funds were provided after the State of Maryland chose TEDCO to be one of the various stewards of this essential funding, allowing for more investments in target communities and areas with small, micro and Socially and Economically Disadvantaged Individual (SEDI) businesses. Click here to learn more.

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.

Based on the safety and tolerability profile observed in the Single Ascending Dose (SAD) cohorts of the study, the Bellberry Human Research Ethics Committee (HREC) in Australia approved the start of the MAD part of the study in parallel with the completion of the last SAD cohorts. Following the HREC approval, administration of GT-02287 in the MAD part of the study has been initiated.

MANASSAS, Va. & TEL AVIV, Israel–(BUSINESS WIRE)–ATCC, the world’s premier biological materials management and standards organization, and Tissue Dynamics, a disruptive pharma-tech company integrating advanced artificial intelligence tools with bionic human organoids, today announced a partnership to develop workflow friendly cardiac organoids-based kits for improved cardiac safety testing in drug development. The collaboration will be done under the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) framework, which awarded both companies a two-year grant. The BIRD Foundation, established in 1977, bolsters transformative partnerships that stimulate, promote, and support industrial research and development in a wide range of technology sectors.

When the Biden Administration unleashed its proposed march-in guidelines last December, it claimed they would be a powerful tool for lowering drug prices by allowing the government to “march in” to license copiers under the authorities of the Bayh-Dole Act.

It did so despite previously joining every other Administration denying price control petitions as not authorized under the law. It should have known the proposal would have minimal impact on drug prices—but would have a devastating impact on American innovation. That’s because the guidelines apply to all federal R&D agencies—not just the National Institutes of Health — so they cover inventions across the spectrum, not just the life sciences.

The Covid-19 pandemic triggered an unexpected boom in entrepreneurship, as Americans opted to start businesses at record rates. Just as unexpected has been the boom’s durability. Would-be entrepreneurs have proven to be undaunted by recession fears, labor and supply-chain constraints, the highest inflation rates in a generation, and rapid interest rate hikes. In October 2023, over three and a half years after the pandemic’s onset, Americans were still filing 59% more applications to start new businesses than they were before the pandemic. The resurgence is all the more remarkable given how deeply startup rates and other measures of economic dynamism languished at or near all-time lows throughout the 2010s.

Thus, one of the most intriguing questions facing the U.S. economy right now is whether the pandemic has durably shaken the country out of its entrepreneurial slump. The answer to this question matters inordinately to the health and direction of the economy in the years ahead, affecting everything from job growth to productivity. And answering it requires digging into three things: what’s driving the boom, how economically significant it may be, and what policymakers can do to sustain it.

Being a university in Washington DC poses interesting challenges, but Georgetown University’s Tatiana Litvin-Vechnyak is determined to turn them into opportunities.

Weirdly, being located at the heart of the US capital doesn’t always help Georgetown University when it comes to creating spinout companies. State universities often have economic development mandates that they can follow, but in Washington DC Georgetown is in something of a vacuum — with little direction for what to focus on, less set funding and fewer people pushing to advance the technologies coming out of the institution.

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

As previously announced,1 the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).2 AIO-001 has the potential to be administered every six months due to its high potency and long half-life, which could redefine the standard-of-care.